Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Rheumatology

Managing Your Future: Monitoring and Long-Term Health in MPA

At a Glance

Managing Microscopic Polyangiitis (MPA) requires vigilant long-term monitoring to catch early signs of relapse. Patients should undergo routine urine and blood tests to protect kidney function, while proactively managing increased risks for infections, cardiovascular disease, and anxiety.

Successfully reaching remission is a major milestone, but for most people with Microscopic Polyangiitis (MPA), the journey shifts from “curing” the disease to managing it as a long-term, chronic condition [1]. Because MPA is a relapsing-remitting disease—meaning it can go through periods of being quiet followed by “flares” of activity—vigilant monitoring is your best tool for staying healthy [2][3].

A Roadmap for Long-Term Monitoring

Surveillance is designed to catch the very first signs of a relapse before they cause new organ damage [4]. While every plan is personalized, typical monitoring often follows this rhythm:

  • Years 1–2 (Active Monitoring): Frequent check-ups, often every 1 to 3 months. This phase focuses on tapering steroids and ensuring maintenance therapy (like Rituximab) is working [5][6].
  • Years 3–5 (Stabilization): If you remain in remission, visits may move to every 3 to 6 months. A key focus here is 3-monthly urinalysis to check for microscopic blood, which can be an early warning sign of a kidney relapse [4][7].
  • Year 10+ (Long-Term Health): Even in long-term remission, yearly follow-ups are usually recommended to monitor for “late” complications like Chronic Kidney Disease (CKD) or heart-related issues [1][8].

Managing Your Relapse Risk

Relapse is common in MPA, but it is not a failure of treatment—it is the nature of the disease [2]. Several factors influence your specific risk:

  • The ANCA Type: Patients who are PR3-ANCA positive generally have a higher risk of the disease returning than those who are MPO-ANCA positive [9][10].
  • The Urine Signal: If blood remains in your urine even when you feel well (persistent hematuria), it is a significant predictor that a kidney relapse may happen in the future [11].
  • Maintenance Success: Sticking with your maintenance therapy (like Rituximab) is the most effective way to lower your risk of a flare [5][12].

Long-Term Health Risks and Complications

Living with MPA means staying mindful of three “excess” risks compared to the general population:

  1. Infection Risk: Because of the medications used to keep the immune system quiet, infection remains the leading cause of “excess” health issues in patients [13][14].
    • Infection Prevention: You must take this seriously. Ensure your vaccinations (e.g., flu, COVID, pneumonia) are up to date before starting Rituximab, which blunts your body’s ability to respond to vaccines [6]. Take your prescribed prophylactic antibiotics without fail. Consider masking in crowded indoor areas, and always call your doctor immediately if you develop a fever or new cough.
  2. Cardiovascular Risk: MPA survivors have a roughly 65% higher risk of heart disease and stroke [15]. Managing blood pressure, cholesterol, and weight is critical [16]. Ask your doctor if moderate cardiovascular exercise is safe for you during your maintenance phase to help offset these risks.
  3. Kidney Function: If your kidneys were damaged during the initial flare, you may develop CKD over time, requiring ongoing monitoring of your GFR (kidney filtration rate) [1][17].

The Psychological Toll: Healing Beyond the Physical

The “mental load” of living with a rare, unpredictable disease is significant. MPA patients often report a lower quality of life than the general population due to fatigue, worry about flares, and medication side effects [18][19].

  • Emotional Health: Anxiety and depression are common in chronic illness survivors [20][21]. It is important to treat these symptoms with the same priority as your physical ones.
  • Quality of Life Improvements: Newer “steroid-sparing” treatments like Avacopan have been shown to not only control the disease but also lead to meaningful improvements in quality-of-life scores [22][23].

Never hesitate to ask for a referral to a counselor or therapist who specializes in chronic illness; your mental resilience is a vital part of your long-term success.

Common questions in this guide

How often do I need to see my doctor after reaching MPA remission?
In the first two years of remission, you will likely have check-ups every 1 to 3 months. If your condition stabilizes, visits may move to every 3 to 6 months to monitor your kidney function and check for early signs of relapse.
Am I at a higher risk for an MPA relapse based on my ANCA type?
Patients who are PR3-ANCA positive typically have a higher risk of the disease returning compared to those who are MPO-ANCA positive. Your doctor will use this information to tailor your long-term monitoring and maintenance plan.
Why do I need to monitor my urine if I feel fine?
Persistent microscopic blood in your urine, even when you feel completely well, is a significant early predictor of a potential kidney flare. Checking your urine regularly helps catch relapses before they cause new organ damage.
What are the long-term health risks of living with MPA?
Long-term risks include a higher chance of serious infections due to immunosuppressive medications, a significantly higher risk of cardiovascular disease, and chronic kidney disease if your kidneys were damaged during an active flare.
How does MPA affect mental health?
Living with a rare, unpredictable disease often causes anxiety, depression, and fatigue. The emotional toll of worrying about flares and managing medication side effects is significant, and seeking support from a specialized counselor is highly recommended.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the plan for my routine monitoring (e.g., how often will we check my urine and blood work)?
  2. 2.Am I at a higher risk of relapse based on my PR3-ANCA or MPO-ANCA status?
  3. 3.What steps are we taking to monitor and reduce my 65% higher risk of cardiovascular disease?
  4. 4.Are my current kidney function levels (GFR) stable, and what signs should I watch for that might indicate a relapse in my kidneys?
  5. 5.How will we balance the need for long-term immunosuppression with my increased risk of serious infections?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Diagnosis and management of ANCA-associated vasculitis.

    Kronbichler A, Bajema IM, Bruchfeld A, et al.

    Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

    PMID: 38368016
  2. 2

    Monitoring disease activity in antineutrophil antibody-associated vasculitis.

    Scurt FG, Hirschfeld V, Schubert L, et al.

    Scandinavian journal of immunology 2023; (98(1)):e13284 doi:10.1111/sji.13284.

    PMID: 37132459
  3. 3

    Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Active Kidney Involvement in the United States: 2016-2020.

    Tao J, Liu S, Montez-Rath M, et al.

    Glomerular diseases 2024; (4(1)):33-42 doi:10.1159/000536168.

    PMID: 38328771
  4. 4

    Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.

    Wester Trejo MAC, Floßmann O, Westman KW, et al.

    Rheumatology (Oxford, England) 2019; (58(1)):103-109 doi:10.1093/rheumatology/key260.

    PMID: 30551161
  5. 5

    Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

    Terrier B, Pagnoux C, Perrodeau É, et al.

    Annals of the rheumatic diseases 2018; (77(8)):1150-1156 doi:10.1136/annrheumdis-2017-212768.

    PMID: 29724729
  6. 6

    Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis.

    Morales E, Rúa-Figueroa I, Callejas Rubio JL, et al.

    Nefrologia 2025; (45(1)):15-58 doi:10.1016/j.nefroe.2025.01.001.

    PMID: 39855968
  7. 7

    Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns.

    Oristrell J, Loureiro-Amigo J, Solans R, et al.

    Clinical and experimental immunology 2021; (203(2)):209-218 doi:10.1111/cei.13530.

    PMID: 33020895
  8. 8

    Clinical associations of renal involvement in ANCA-associated vasculitis.

    Kronbichler A, Shin JI, Lee KH, et al.

    Autoimmunity reviews 2020; (19(4)):102495 doi:10.1016/j.autrev.2020.102495.

    PMID: 32068190
  9. 9

    Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.

    Hong Y, Shi P, Liu X, et al.

    Clinical rheumatology 2019; (38(6)):1665-1673 doi:10.1007/s10067-019-04458-9.

    PMID: 30737591
  10. 10

    ANCA-associated vasculitis in the United Arab Emirates: a 17-year case series with review from Gulf literature.

    Shahrour H, Luqman N, AlKindi F, et al.

    Annals of Saudi medicine 2026; (46(1)):20-31 doi:10.5144/0256-4947.2026.20.

    PMID: 41562166
  11. 11

    The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

    Rhee RL, Davis JC, Ding L, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2018; (13(2)):251-257 doi:10.2215/CJN.04160417.

    PMID: 29371340
  12. 12

    Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.

    Watanabe R, Oshima M, Nishioka N, et al.

    Modern rheumatology 2023; (33(5)):982-989 doi:10.1093/mr/roac114.

    PMID: 36112482
  13. 13

    All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.

    Wallace ZS, Fu X, Harkness T, et al.

    Rheumatology (Oxford, England) 2020; (59(9)):2308-2315 doi:10.1093/rheumatology/kez589.

    PMID: 31846030
  14. 14

    Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis.

    Kitagawa K, Furuichi K, Sagara A, et al.

    Clinical and experimental nephrology 2016; (20(5)):703-711 doi:10.1007/s10157-015-1199-7.

    PMID: 26590051
  15. 15

    Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.

    Houben E, Penne EL, Voskuyl AE, et al.

    Rheumatology (Oxford, England) 2018; (57(3)):555-562 doi:10.1093/rheumatology/kex338.

    PMID: 29029294
  16. 16

    Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

    Lee SB, Kwon HC, Kang MI, et al.

    Rheumatology international 2022; (42(2)):291-302 doi:10.1007/s00296-021-04908-1.

    PMID: 34086074
  17. 17

    Clinical characteristics and prognosis in 269 patients with antineutrophil cytoplasimc antibody associated vasculitis.

    Wu T, Zhong Y, Zhou Y, et al.

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2020; (45(8)):916-922 doi:10.11817/j.issn.1672-7347.2020.190436.

    PMID: 33053532
  18. 18

    Health-related quality of life and work productivity in Japanese patients with primarily stable ANCA-associated vasculitis: A multicenter cross-sectional study.

    Hirahara S, Katsumata Y, Sada KE, et al.

    Modern rheumatology 2025; (35(6)):974-980 doi:10.1093/mr/roaf044.

    PMID: 40445196
  19. 19

    Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis.

    Mercuzot C, Letertre S, Daien CI, et al.

    Autoimmunity reviews 2021; (20(1)):102708 doi:10.1016/j.autrev.2020.102708.

    PMID: 33212227
  20. 20

    Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension.

    Dering MR, Lepsy N, Fuge J, et al.

    Frontiers in psychiatry 2022; (13()):821466 doi:10.3389/fpsyt.2022.821466.

    PMID: 35308878
  21. 21

    Prevalence of psychological distress among cancer patients in Southeast Asian countries: A systematic review.

    Ostovar S, Modarresi Chahardehi A, Mohd Hashim IH, et al.

    European journal of cancer care 2022; (31(6)):e13669 doi:10.1111/ecc.13669.

    PMID: 35934684
  22. 22

    The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

    Strand V, Jayne DRW, Horomanski A, et al.

    The Lancet. Rheumatology 2023; (5(8)):e451-e460 doi:10.1016/S2665-9913(23)00092-9.

    PMID: 38251577
  23. 23

    Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Merkel PA, Niles J, Jimenez R, et al.

    ACR open rheumatology 2020; (2(11)):662-671 doi:10.1002/acr2.11185.

    PMID: 33128347

This page is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or nephrologist about your specific MPA management and monitoring plan.

Get notified when new evidence is published on Microscopic polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.